Sunshine Biopharma, Inc.
SBFM
$1.25
$0.032.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -80.18% | -142.32% | 61.50% | -2.70% | -91.86% |
| Total Depreciation and Amortization | 1.24% | 26.92% | 19.48% | 0.47% | 13.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -100.00% | 2,900.00% | 200.00% |
| Change in Net Operating Assets | -477.04% | 94.49% | -111.37% | -31.95% | -1,041.80% |
| Cash from Operations | -150.35% | 70.27% | -43.72% | -18.42% | -488.17% |
| Capital Expenditure | 80.15% | 46.95% | -1,449.28% | -116.45% | 4,083.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -598.53% | -114.20% | 171.36% | 7.03% | -2,386.32% |
| Cash from Investing | 8.11% | -6.68% | 18.92% | -148.40% | -1,524.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 395.96% | -3.85% | 3.38% | 10.03% | -12.29% |
| Issuance of Common Stock | -14.63% | -- | -100.00% | 372,395.65% | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.08% | 6,624.48% | -100.53% | 17,798.69% | 52.04% |
| Foreign Exchange rate Adjustments | -182.26% | 199.28% | -93.32% | -192.38% | 214.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -460.58% | 111.79% | -619.00% | 144.71% | -189.09% |